IP Library Granted Patent US 10,920,191
Granted Patent B2
US 10,920,191 · App. 15/846,181 · Granted Feb 16, 2021

Methods of screening embryonic progenitor cell lines

Inventors: Michael West (Mill Valley, CA); Hal Sternberg (Berkeley, CA); Karen Chapman (Mill Valley, CA)
Assignee: LINEAGE CELL THERAPEUTICS, INC.
C12N5/0606C12N5/0653
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,920,191
App. No.
15/846,181
Granted
Feb 16, 2021
Kind
B2
Abstract

Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion. The robustness of these clonally-purified lines, their ability to expand for >40 passages while maintaining their pattern of gene expression, lack of tumorigenicity, and their embryonic pattern of gene expression offers novel compositions and methods for modeling numerous differentiation pathways for the first time in vitro, and for the manufacture of purified product not existing in such a purified state in nature or using other manufacturing modalities. Representative progenitor cell lines described herein are capable of development into cutaneous adipocytes, blood-brain barrier cells, neuronal cells, or smooth muscle cells each with therapeutic potential.

Claims (6)

1. An isolated clonal progenitor cell line expressing EYA4, ADH1A and ADH1B, wherein the clonal progenitor cell line is an in vitro human pluripotent stem cell-derived embryonic cutaneous progenitor cell line and wherein the clonal progenitor cell line is encapsulated in a biomaterial.

2. The isolated clonal progenitor cell line of claim 1 , wherein the cell line also expresses FABP4, CD36, PPARG, ANGPT2, EBF2 and DBC1.

3. The isolated clonal progenitor cell line of claim 1 , wherein the biomaterial comprises a hydrogel.

4. The isolated clonal progenitor cell line of claim 1 , wherein the biomaterial comprises hyaluronic acid.

5. The isolated clonal progenitor cell line of claim 1 , wherein the biomaterial is chosen from calcium alginate, agarose, polylactic acid/polyglycolic acid derivatives, and fibrin.

6. A kit comprising the cell line of claim 1 .

Assignments (1)
CHANGE OF NAME Recorded Feb 26, 2020
From: BIOTIME, INC.
To: LINEAGE CELL THERAPEUTICS, INC.
Reel/Frame 052024/0796 →
Continuity (16)
Continuation 13683241 · Nov 21, 2012
Continuation In Part PCTUS2011037969 · May 25, 2011
Continuation In Part 13384289
Continuation In Part 12504630 · Jul 16, 2009
Provisional Application 61349081 · May 27, 2010
Provisional Application 61415321 · Nov 18, 2010
Provisional Application 61383679 · Sep 16, 2010
Provisional Application 61379321 · Sep 1, 2010
Provisional Application 61426301 · Dec 22, 2010
Provisional Application 61226237 · Jul 16, 2009
Provisional Application 61243939 · Sep 18, 2009
Provisional Application 61349088 · May 27, 2010
Provisional Application 61365308 · Jul 16, 2010
Provisional Application 61081325 · Jul 16, 2008
Provisional Application 61178457 · May 14, 2009
Related Publication 20190241867A1 · Aug 8, 2019
Cited By (1)
US 12,692,476